Skip to main content
. Author manuscript; available in PMC: 2006 May 30.
Published in final edited form as: J Am Coll Surg. 2004 May;198(5):685–696. doi: 10.1016/j.jamcollsurg.2004.01.025

Table 6.

Identification of Class II Restricted Cancer Antigens

Name of antigen Method of identification HLA restriction Epitope Characteristics
CDC-27 TIL 1359 DR4 FSWAMDLDPKGA Mutation resulting in aberrant processing
LDLR/FUT TIL 1363-C22 DR1 WRRAPAPGA Chromosomal arrangement
TP1 TIL 155 DR1 ELIGILNAAKVPAD Mutation; confirmed prior identification of Topalian and colleagues
NY-ESO-1 Peptide screening; DR4 VLLKEFTVSG Cancer-testis antigen
transgenic mice
Peptide screening DR4 SLLMWITQCFLPVF Contains both A2 Class I and DP Class II epitopes
TRP-1/TRP-2 TIL 1541C8 DR15 ?EPSFSLPYWNFATGKNVC Non-mutated; identified by screening
?NESFALPYWNFATGRNEC candidates
gp100 Peptide screening; DR4 WNRQLYPEWTEAQRLD Non-mutated; identified by screening
transgenic mice candidates
TIL 1290C6 DR15 (Pending) –
Ki-67 TIL 1290C2 DR16 (Pending) Mutated; expression limited to proliferating cells